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The Current Role of Intra-arterial Thrombolysis
T. Richards, A. A. Pittathankal, T. R. Magee and R. B. Galland
Vascular Unit, Department of Surgery, Royal Berkshire Hospital, London Road, Reading RG1 5AN, U.K.
Background: the role of intra arterial thrombolysis (IAT) in the management of peripheral vascular disease has come under
scrutiny. This study aims to assess current usage and indications for IAT in the U.K.
Method: the use of IAT was assessed at our own centre and a questionnaire was sent to all centres that provide data for the
U.K. `` Thrombolysis Study Group''.
Results: there has been a steady decline in the use of IATat our centre from a peak of 40 cases per annum to zero. Response was
received from 22 of 24 centres (92%). Nineteen (86%) reported a decline in IATuse. Main reasons were concerns over lack of
efficacy (74%) and complication rate (63%). Most centres would use IAT for acute limb ischaemia (86%). However, for acute
thrombosis in specific indications the results varied; synthetic graft (82%), vein graft (54%), supra-inguinal graft (54%) and
thrombosed popliteal artery aneurysm (54%). When asked what their commonest usage for IATwas, the results again varied;
acute limb ischaemia (40%), graft thrombosis (40%), embolism post radiological intervention (12%), other (8%).
Conclusion: there has been a significant decrease in IAT use. Concerns exist as to efficacy and complication rate. There is
no clear consensus on indications.
Key Words: Thrombolysis; Peripheral; Indication.
Introduction
From its inception by Dotter in 1974,1 there was a gain
in popularity for the use of intra arterial thrombolysis
(IAT). In the U.K. IAT had a mixed reception. Difficul-
ties with staff and high dependency bed availability
hampered the adoption of IAT. Concern was ex-
pressed about complications, and also efficacy.2
Many surgeons felt that cases suitable for IAT should
be managed in specialist centres by experienced
vascular surgeons.3
The aims of this paper are to assess whether IAT
remains a popular treatment in the management of
peripheral vascular disease and for what indications
it is currently used in the U.K.
Methods
We reviewed the use of IAT at our own centre, where
there are two vascular surgeons and three interven-
tional radiologists serving a population of approxi-
mately 460 000. Numbers of episodes of thrombolysis
were prospectively recorded. Annual rates were
calculated.
To gain a national perspective, a questionnaire was
sent to each of the centres participating in the U.K.
`` Thrombolysis Study Group''. Established in 1992,
this group comprises specialist vascular centres
throughout the U.K. with an interest in IAT. Details
from cases are centrally recorded on the National
Audit of Thrombolysis for Acute Leg Ischaemia
(NATALI) database.4 With experience from over 1200
cases this group represents those centres in the U.K.
that regularly use IAT.
To gain information about IAT use, each centre was
asked: `` Compared with 5±10 years ago, has your cur-
rent practice of IAT increased, decreased or stayed
the same?'' `` Can you give figures for; number of IAT
procedures in 2001, maximum number that you
undertook in a previous year?'' `` If the use of IAT has
decreased, what are the reasons for this?''
To assess current practice of IAT, each centre was
asked a series of questions (Fig. 1). They were also
asked `` What is the commonest indication for IAT in
your unit at the moment?''
Data were collated on an Excel database
(Microsoft Office 2000). Non-parametric data were
analysed by Mann±Whitney test (Prism 2.01, Graftpad
software).
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Would you use IAT in the following clinical situations? 
Always Sometimes Rarely Never
No neurosensory deficit Acute limb 
ischaemia Some neurosensory deficit 
Sudden worsening symptoms (days) In a patient with
claudication Worsening symptoms (weeks) 
Embolism following angiography 
Would you use IAT for the treatment of acute thrombosis of the following? 
Always Sometimes Rarely Never
Popliteal aneurysm. 
Supra-inguinal graft 
Synthetic Fem-pop 
bypass graft Vein 
Synthetic Fem-distal 
bypass graft Vein 
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over weeks (Table 1). When asked about specific
indications, there was no difference between
femoral-popliteal and femoral-distal bypass grafts.
Most (82%) would use IAT `` always'' or `` sometimes''
for acute thrombosis of a synthetic graft. This was
lower (54%) for a vein graft. There was no clear con-
sensus for IAT use in acute thrombosis of grafts above
the inguinal ligament (54%) or for acute thrombosis of
a popliteal artery aneurysm (54%) (Table 2).
When asked the commonest indication for IAT in
their unit results were varied. The most common
indications were graft occlusion (40%) and acute
limb ischaemia (40%). Less common were embolism
following angiography (12%), intra-operative use (4%)
and in the upper limb (4%). In the three centres that
did not report a decline in the use of IAT the most
common indication was graft occlusion.
Discussion
There has been a steady decline in the use of IAT in
our unit. This has not been matched by a rise in major
amputation rate (unpublished data). This decline in
IAT use is representative of a national trend within
the U.K. `` Thrombolysis Study Group'' over the last
decade. A few centres maintain the same level of use
IAT, although this is the exception. The main reason
for this decline was concern about the long-term
efficacy. In theory IAT is an ideal treatment. Peripheral
vascular disease progresses symptomatically in a step-
wise manner due to thrombus formation on a pre-
existing atherosclerotic lesion in the arterial vessel
wall. To dissolve and disperse this thrombus by IAT
would be extremely beneficial. However, in practice
no significant benefits in terms of limb salvage or
death at one year have been demonstrated from the
use of IAT over surgery.5 However, IAT use may
reduce the extent of surgery or even the need for
open surgery.6±8 Recommendations suggest that IAT
should be used in combination with other procedures,
to define the underlying problem that is then treated
either by angioplasty or surgery.9
In two thirds of centres concern about the complica-
tions of IAT were regarded as the main reason for fall
in IAT usage. Main complications are intracranial
haemorrhage (1±2%) and major haemorrhage
(5±12%).10,11 Risks are increased in the elderly.12
Acute limb deterioration during thrombolysis can
also happen.7,13 It is interesting to note that a lack of
`` back up'' remains an issue in these centres that have
experience and have commonly used IAT. This figure
remains unchanged from a previous survey in 1991.2
IAT remains popular for management of ALI with-
out neurological deficit due to acute thrombosis. The
role of IAT in worsening claudication is less popular
and in keeping with the literature.14,15 However, these
results suggest that despite this, many would still
on occasion use it. For worsening claudication over
weeks most would never use IAT, an indication now
obsolete.16
The response for IAT in management of acute graft
thrombosis is varied and confusing. Initial results
from our centre supported the role of IAT in the man-
agement of occluded bypass graft particularly in
suprainguinal grafts.17 Sub group analysis of the
STILE data suggested a benefit but failed to reach
statistical significance.18 However, further analysis
from the NATALI database revealed that patency on
an intention to treat basis is approximately 20% at one
year.19 Despite this, graft thrombosis remains one of
the most popular indications for IAT amongst the
same group. The response for management of throm-
bosed popliteal artery aneurysm is mixed. This condi-
tion has a high rate of amputation and the use of IAT
to salvage a limb may only delay revascularisation.20
Those with demonstrable runoff should not
undergo IAT.9
An interesting point from this trial is that despite
results identifying those patients groups who do not
benefit from IAT (elderly,12 graft thrombosis19 and IAT
for acute worsening claudication14), centres are still
Table 1. IAT use amongst centres in the Thrombolysis Study
Group. Number of centres who would use IAT for acute limb
ischaemia (ALI) with no neurosensory deficit or with deficit, a
patient with claudication (IC) with sudden worsening symptoms
(days) or worsening symptoms (weeks). Answers were graded
`` always'', `` sometimes'', `` rarely'' or `` never''.
IAT use Always Sometimes Rarely Never
ALI 1 16 5 0
ALI (neurosensory deficit) 0 12 5 4
IC (days) 0 4 10 8
IC (weeks) 0 1 4 16
Table 2. Indication for IAT amongst centres in the Thrombolysis
Study Group. Number of centres that would use IAT for acute
thrombosis of; lower limb bypass graft (synthetic or vein) , supra-
inguinal graft, or popliteal artery aneurysm. Answers were graded
`` always'', `` sometimes'', `` rarely'' or `` never''.
Indication Always Sometimes Rarely Never
Synthetic graft 3 14 4 1
Vein graft 2 10 9 1
Supra-inquinal graft 1 11 5 5
Popliteal artery aneurysm 1 11 8 2
There was no difference between femoral-popliteal and femoral-
distal bypass grafts so these responses are combined.
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using IAT for these indications. Graft thrombosis
being the most common indication particularly in the
three centres that still commonly use IAT.
One of the main confusions about the indications
for IAT has ironically been the STILE and TOPAS
trials. These incorporated a heterogeneous mixture of
cases. Patients with ALI or worsening claudication
due to thrombosis or embolism occurring throughout
the peripheral vascular system or in bypass grafts
were all included and compared. There was no initial
stratification by pathogenesis, location or symptoms.
Subgroup analysis was consequently flawed by small
numbers, either directly in the trial or combined with
others after meta-analyses.5,21 Despite this a small
subgroup of patients (10±30%) in these and subse-
quent trials underwent IAT with good results, without
complications and requiring no further intervention.
The question remains who these are and how they can
be identified.
Current roles that remain to be analysed for IAT are
embolism following intervention and intraoperatively
to clear smaller vessels following failed embolectomy.
These represent small patient numbers. The role of
IAT in the management of ALI due to native vessel
thrombosis remains to be assessed. Acute leg ischae-
mia (ALI) leads to a high patient mortality and mor-
bidity. Early attempts to address this centred on
presenting features by stratifying the cases as viable,
threatened or non-viable.22 The appropriate operation
and timing for surgery was shown to reduce the mor-
tality and need for subsequent operations.23 More
recently the use of P-POSSUM scoring to assess
patients prior to IAT has been predictive of outcome.24
Have we now come full circle after the initial
enthusiasm?
Conclusion
In the last decade there has been a significant decrease
in the use of IAT in the U.K. Thrombolysis Study
Group. Concerns exist as to the efficacy and complica-
tion rate. Of those still using IAT acute limb ischaemia
and graft thrombosis are the most common
indications.
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